STOCKSCREENR
Log In

LXEO

NASDAQ

Lexeo Therapeutics, Inc. Common Stock

$6.38-0.19(-2.89%)Mkt Cap: $465.66M

Key Stats

Market Cap

$465.66M

P/E Ratio

-2.55

EPS

$-2.50

Dividend Yield

0.00%

52-Week Range

$1.45 — $10.99

Volume

629.02K

Avg Volume

1.15M

Beta

1.80

Valuation

P/E (TTM)

-2.55

Forward P/E

—

PEG Ratio

-0.22

P/S (TTM)

0.00

P/B (TTM)

3.35

P/FCF

—

EV/EBITDA

—

EV/Sales

—

Financial Health

ROE (TTM)

-0.90%

ROA (TTM)

-0.73%

ROIC

—

Gross Margin

0.00%

Operating Margin

0.00%

Net Margin

—

Debt/Equity

0.07

Current Ratio

7.40

Growth

EPS Growth (YoY)

—

Revenue Growth (YoY)

—

EPS Growth (3Y)

-0.16%

EPS Growth (5Y)

-1.90%

Sales Growth (3Y)

-0.54%

Sales Growth (5Y)

+0.12%

EPS Est (This Year)

$-1.52

EPS Est (Next Year)

$-1.35

Dividends

Dividend Yield

—

Annual Dividend

—

Payout Ratio

—

Frequency

—

Ex-Dividend Date

—

Cash/Share

$0.67

Analyst Consensus

Price Target Range

$10.00$20.00$30.00
LowMedianHigh

Consensus Target: $20.14(215.7% upside)

Ownership

Institutional %

—

Inst. Net Change

—

Insider Net Shares (90d)

—

Outstanding Shares

72.99M

Float

47.70M

Free Float %

65.35%

About

Sector

Healthcare

Industry

Biotechnology

Country

US

Exchange

NASDAQ

IPO Date

2023-11-03

Employees

75

CEO

R. Nolan Townsend

Index Membership

—

Website

https://www.lexeotx.com

Lexeo Therapeutics, Inc. Common Stock (LXEO) is a healthcare company in the biotechnology industry listed on the NASDAQ. With a market capitalization of $465.66M, a P/E ratio of -2.55, LXEO is tracked by stockscreenr alongside 25,000+ other tickers. Use the free stock screener to compare LXEO against other stocks using dozens of fundamental and technical filters.

Similar Stocks

CYBN

Cybin Inc.

$8.28

+1.22%

$413.02M

FRX.TO

Fennec Pharmaceuticals Inc.

$10.72

-0.05%

$295.33M

BTX

BlackRock Technology and Private Equity Term Trust

$6.49

+1.56%

$757.45M

BHVN

Biohaven Ltd.

$9.53

-1.14%

$1.01B

STOK

Stoke Therapeutics, Inc.

$32.87

-3.21%

$1.88B

SNDX

Syndax Pharmaceuticals, Inc.

$23.77

-1.12%

$2.10B

Frequently Asked Questions

What is Lexeo Therapeutics, Inc. Common Stock's P/E ratio?

Lexeo Therapeutics, Inc. Common Stock (LXEO) has a trailing twelve-month (TTM) P/E ratio of -2.55. This is below the market average, which may suggest the stock is undervalued or has lower growth expectations. The P/E ratio measures how much investors are willing to pay per dollar of earnings.

Does Lexeo Therapeutics, Inc. Common Stock pay a dividend?

No, Lexeo Therapeutics, Inc. Common Stock (LXEO) does not currently pay a regular dividend. The company may be reinvesting profits into growth, research, or debt reduction instead of returning cash to shareholders through dividends.

What is Lexeo Therapeutics, Inc. Common Stock's market cap?

Lexeo Therapeutics, Inc. Common Stock (LXEO) has a market capitalization of $465.66 million, classifying it as a small-cap company. Market cap is calculated by multiplying the current share price by the total number of outstanding shares.